These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38320035)

  • 1. A Pragmatic Randomized Feasibility Trial of Influenza Vaccines.
    Johansen ND; Modin D; Nealon J; Samson S; Salamand C; Loiacono MM; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    NEJM Evid; 2023 Feb; 2(2):EVIDoa2200206. PubMed ID: 38320035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults.
    Palmu AA; Pepin S; Syrjänen RK; Mari K; Mallett Moore T; Jokinen J; Nieminen H; Kilpi T; Samson SI; De Bruijn I
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13270. PubMed ID: 38569647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
    Lassen MCH; Johansen ND; Modin D; Nealon J; Samson S; Dufournet M; Loiacono MM; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Krause TG; Biering-Sørensen T
    Diabetes Obes Metab; 2024 May; 26(5):1821-1829. PubMed ID: 38586966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial.
    Johansen ND; Modin D; Skaarup KG; Nealon J; Samson S; Dufournet M; Loiacono MM; Harris RC; Larsen CS; Jensen AMR; Landler NE; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    Clin Microbiol Infect; 2024 Nov; 30(11):1453-1459. PubMed ID: 38286177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial.
    Johansen ND; Modin D; Nealon J; Samson S; Salamand C; Larsen CS; Claggett BL; Solomon SD; Landray MJ; Gislason GH; Køber L; Jensen JUS; Sivapalan P; Vestergaard LS; Valentiner-Branth P; Krause TG; Biering-Sørensen T
    Pilot Feasibility Stud; 2022 Apr; 8(1):87. PubMed ID: 35449028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial.
    Hollingsworth R; Palmu A; Pepin S; Dupuy M; Shrestha A; Jokinen J; Syrjänen R; Nealon J; Samson S; De Bruijn I
    Am Heart J; 2021 Jul; 237():54-61. PubMed ID: 33722585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Chen JY; Hsieh SM; Hwang SJ; Liu CS; Li X; Fournier M; Yeh TY; Yin JK; Samson SI
    Vaccine; 2022 Oct; 40(45):6450-6454. PubMed ID: 36216650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.
    Schuster JE; Hamdan L; Dulek DE; Kitko CL; Batarseh E; Haddadin Z; Stewart LS; Stahl A; Potter M; Rahman H; Kalams SA; Bocchini CE; Moulton EA; Coffin SE; Ardura MI; Wattier RL; Maron G; Grimley M; Paulsen G; Harrison CJ; Freedman JL; Carpenter PA; Englund JA; Munoz FM; Danziger-Isakov L; Spieker AJ; Halasa NB;
    Clin Infect Dis; 2024 Jan; 78(1):217-226. PubMed ID: 37800415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.
    Esposito S; Nauta J; Lapini G; Montomoli E; van de Witte S
    Vaccine; 2022 Apr; 40(18):2626-2634. PubMed ID: 35315323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
    Rumi F; Basile M; Cicchetti A; Alvarez FP; Azzi MV; Muzii B
    Front Public Health; 2023; 11():1200116. PubMed ID: 38026422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
    Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
    Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
    Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
    BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ
    Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.